Beam Therapeutics (BEAM) Net Cash Flow (2019 - 2026)

Beam Therapeutics (BEAM) has reported Net Cash Flow for 8 consecutive years, with -$6.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Cash Flow fell 102.72% year-over-year to -$6.6 million; the TTM figure through Mar 2026 stood at -$239.5 million (down 199.72% YoY), while the FY2025 annual figure was $11.5 million, up 107.45% from the prior year.
• Net Cash Flow declined to -$6.6 million in Q1 2026 per BEAM's latest filing, from $27.0 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $266.9 million in Q4 2023 and bottomed at -$263.2 million in Q1 2022.
• Historically, Net Cash Flow has averaged -$16.3 million across 5 years, with a median of -$14.1 million in 2025.
• On a YoY basis, Net Cash Flow climbed as much as 262.6% in 2025 and fell as far as 5422.76% in 2025.
• Beam Therapeutics' Net Cash Flow stood at $76.3 million in 2022, then surged by 249.97% to $266.9 million in 2023, then sank by 80.01% to $53.4 million in 2024, then sank by 49.39% to $27.0 million in 2025, then sank by 124.57% to -$6.6 million in 2026.
• Business Quant data shows BEAM's Net Cash Flow at -$6.6 million in Q1 2026, $27.0 million in Q4 2025, and -$14.1 million in Q3 2025.